Background
Methods
Research protocol overview
Search strategies
Inclusion and exclusion criteria
Number | Inclusion criteria |
1 | Original prospective cohort studies or randomized controlled trials (RCTs) published in full text and those for which we had full access to all original data and protocols. |
2 | The studies evaluated the differences of the effect of propofol and sevoflurane on postoperative cognitive functions. |
3 | Regarding the intervening measures between different groups, the only difference is that the two groups received propofol or sevoflurane, respectively. Other conditions should be the same. |
4 | Human studies. |
5 | Predefined outcomes: incidence of postoperative MMSE scores and the plasma protein S100β at various time points. |
6 | No minimal sample size or dosing regimen was required for inclusion. |
Number | Exclusion criteria |
1 | The study did not have a control group of patients without propofol use or sevoflurane use. |
2 | They were case studies or case series. |
3 | The report focused exclusively on other topics or outcomes. |
4 | No human data were included. |
5 | Except for the difference of anaesthetic administration, there were other differences between the experimental groups and the control groups. |
6 | Reviews and duplicated publications. |
Data extraction and quality evaluation
Author | Year | Country | Sex (M/F) | Age | Surgery | ASA grade | Outcomes | Propofol group | Sevoflurane group | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Method | No. | Method | No. | ||||||||
Yu et al. | 2012 | China | 44 /36 | 68.8 ± 3.8 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: propofol | 40 | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: sevoflurane | 40 |
Tang et al. | 2014 | China | 38 /32 | 70.0 ± 11.7 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: etomidate, midazolam, fentanyl, rocuronium; Maintain: propofol | 35 | Induction: etomidate, midazolam, fentanyl, rocuronium; Maintain: sevoflurane | 35 |
Sun et al. | 2014 | China | 77 /29 | 72.2 ± 2.6 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: fentanyl and vecuronium bromide; Maintain: propofol 2~4 mg/kg/min | 53 | Induction: fentanyl and vecuronium bromide; Maintain: sevoflurane | 53 |
Cui et al. | 2015 | China | 94 /76 | 69 ± 12.9 | Lung cancer operation | N | ①③⑤⑥ | Induction: fentanyl, etomidate, vecuronium bromide; Maintain: propofol 2~4 mg/kg/min | 80 | Induction: fentanyl, etomidate, vecuronium bromide; Maintain: sevoflurane 1%~ 3% | 80 |
Zhang et al. | 2016 | China | 101 /91 | 60.0 ± 6.4 | Lung cancer operation | N | ①③④⑥ | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: propofol | 96 | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: sevoflurane | 96 |
Wang H et al. | 2015 | China | 41 /31 | 73.5 ± 2.8 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: unified rapid induction; Maintain: propofol | 36 | Induction: unified rapid induction; Maintain: sevoflurane | 36 |
Wang F et al. | 2017 | China | 32 /18 | 72.5 ± 3.0 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: propofol | 50 | Induction: midazolam, fentanyl, rocuronium, etomidate; Maintain: sevoflurane | 50 |
Zhao et al. | 2014 | China | 80 /30 | 73.5 ± 2.0 | Lung cancer operation | I~II | ①②③④⑤⑥ | Induction: fentanyl and vecuronium bromide; Maintain: propofol 2~4 mg/kg/min | 50 | Induction: fentanyl and vecuronium bromide; Maintain: sevoflurane | 60 |
Chen et al. | 2015 | China | 43 /35 | 69.2 ± 3.2 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: midazolam, propofol, fentanyl and vecuronium bromide; Maintain: propofol 6~10 mg/kg/min | 39 | Induction: midazolam, propofol, fentanyl and vecuronium bromide; Maintain: sevoflurane | 39 |
Huang et al. | 2015 | China | 50 /40 | 68.2 ± 1.3 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: rocuronium, fentanyl, midazolam, etomidate; Maintain: propofol | 45 | Induction: rocuronium, fentanyl, midazolam, etomidate; Maintain: sevoflurane | 45 |
Lin et al. | 2017 | China | 54/40 | 68.23 ± 1.32 | Lung cancer operation | I~II | ①②③④⑥ | Induction: propofol, midazolam, vecuronium, fentanyl; Maintain: propofol | 40 | Induction: propofol, midazolam, vecuronium, fentanyl; Maintain: sevoflurane | 54 |
Zhang et al. | 2017 | China | 41/29 | P: 74.8 ± 2.1; S: 74.3 ± 2.5 | Lung cancer operation | I~II | ②③④ | Induction: fentanyl, etomidate, midazolam, rocuronium; Maintain: propofol | 35 | Induction: fentanyl, etomidate, midazolam, rocuronium; Maintain: sevoflurane | 35 |
Yang et al. | 2017 | China | 84/36 | 71.9 ± 2.5 | Lung cancer operation | N | ①②③④⑤⑥ | Induction: unified rapid induction; Maintain: propofol | 60 | Induction: unified rapid induction; Maintain: sevoflurane | 60 |
Tian et al. | 2017 | China | 38/24 | P: 68.3 ± 13.5; S: 65.5 ± 16.2 | Lung cancer operation | I~II | ①③⑥ | Induction: midazolam, fentanyl, propofol; Maintain: propofol | 31 | Induction: midazolam, fentanyl, sevoflurane; Maintain: propofol | 31 |
Patient involvement
Statistical analysis
Goals and Usages | Statistic Methods | Explanations and Instructions |
---|---|---|
To evaluate heterogeneity between the included studies | Galbr plot | In Galbr figure, if the points all fall within the area between the upper line and the lower line, it can be taken as an evidence of homogeneity; otherwise, there is heterogeneity. |
Cochran’s Q test | Cochran’s Q test is an extension to the McNemar test for related samples that provides a method for testing for differences between three or more matched sets of frequencies or proportions. Heterogeneity was also considered significant if P < 0.05 using the Cochran’s Q test. | |
I2 index test | The I2 index measures the extent of true heterogeneity dividing the difference between the result of the Q test and its degrees of freedom (k – 1) by the Q value itself, and multiplied by 100. I2 values of 25, 50 and 75% were used as evidence of low, moderate and high heterogeneity, respectively. | |
To examine the stability of the pooled results | Sensitivity analysis | A sensitivity analysis was performed using the one-at-a-time method, which involved omitting one study at a time and repeating the meta-analysis. If the omission of one study significantly changed the result, it implied that the result was sensitive to the studies included. |
Publication bias test | Contour-enhanced funnel plot | Visual inspection of the Contour-enhanced funnel plots was used to assess potential publication bias. Asymmetry in the plots, which may be due to studies missing on the left-hand side of the plot that represents low statistical significance, suggested publication bias. If studies were missing in the high statistical significance areas (on the right-hand side of the plot), the funnel asymmetry was not considered to be due to publication bias |
Results
Search results
Database | Database URL | Search strategy | Results | |
Pubmed | (“sevoflurane” [Supplementary Concept] OR “sevoflurane” [All Fields]) AND (“propofol” [MeSH Terms] OR “propofol” [All Fields]) AND (“lung” [MeSH Terms] OR “lung” [All Fields]) | 108 | ||
Embase | (‘sevoflurane’/exp. OR sevoflurane) AND (‘propofol’/exp. OR propofol) AND (‘lung’/exp. OR lung) | 1131 | ||
Cochrane Library | Sevoflurane AND Propofol AND lung:ti, ab, kw | 148 | ||
Web of Science | TOPIC: (Sevoflurane AND Propofol AND postoperative AND pain); Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, ESCI. | 195 | ||
CNKI | Search conditions: (topic = sevoflurane propofol lung cancer) (fuzzy matching), album navigation: all; database: literature cross-database search; search method: cross-database search Database: Literature | 44 | ||
Searching results and information of relevant academic meeting abstracts | ||||
Year | City | Meeting name | Article title | Whether included |
2015 | Beijing, P.R. China | Chinese seminar on translational medicine and integrative medicine | Difference of postoperative cognitive functions under propofol or sevoflurane anesthesia for lung cancer surgery | No |
Patient characteristics
Meta-analysis results and bias assessment results
Comparative items | Data type | Heterogeneity test | Test of Association | Publication bias | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MMSE and protein marker | Items | Q value | d.f. | I-squared | Tau-squared | P Value | Heterogeneity | Effect model | Pooled WMD | WMD 95% CI | Pooled SMD | SMD 95% CI | Z value | P value | Statistical significance | ||
Preoperative cognitive function | Preoperative MMSE | Continuous | 55.09 | 12 | 78.2% | 0.1449 | 0.000 | Yes | Random | -0.040 | [−0.288, 0.208] | − 0.038 | [− 0.274, 0.198] | 0.31 | 0.753 | No | No |
Postoperative cognitive function evaluation | MMSE 6 h | Continuous | 199.17 | 10 | 95.0% | 1.0826 | 0.000 | Yes | Random | −1.922 | [−2.571, − 1.274] | −1.391 | [− 2.024, −0.757] | 4.30 | 0.000 | Yes | No |
MMSE 24 h | Continuous | 216.54 | 13 | 94.0% | 0.7859 | 0.000 | Yes | Random | −1.504 | [−2.253, −0.755] | − 1.106 | [− 1.588, − 0.624] | 4.50 | 0.000 | Yes | No | |
MMSE 3d | Continuous | 140.36 | 10 | 92.9% | 0.6585 | 0.000 | Yes | Random | −1.376 | [−2.044, −0.708] | − 1.065 | [− 1.564, − 0.566] | 4.19 | 0.000 | Yes | No | |
MMSE 7d | Continuous | 16.75 | 9 | 46.3% | NA | 0.053 | No | fixed | −0.371 | [−0.493, − 0.249] | −0.422 | [− 0.549, − 0.295] | 6.52 | 0.000 | Yes | No | |
Protein marker S100β | S100β 1d | Continuous | 67.94 | 12 | 82.3% | 0.2024 | 0.000 | Yes | Random | 0.018 | [0.016, 0.020] | 0.746 | [0.475, 1.017] | 5.39 | 0.000 | Yes | No |
Author | Year | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other sources of bias |
---|---|---|---|---|---|---|---|---|
Yu et al. | 2012 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Tang et al. | 2014 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Sun et al. | 2014 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Cui et al. | 2015 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Zhang et al. | 2016 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Wang H et al. | 2015 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Wang F et al. | 2017 | Random number table | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Zhao et al. | 2014 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Chen et al. | 2015 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk |
Huang et al. | 2015 | Random number table | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Lin et al. | 2017 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Zhang et al. | 2017 | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear risk | Unclear risk |
Yang et al. | 2017 | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk |
Tian et al. | 2017 | Low risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear risk |